Aramon Neuro-Medical

Company Overview

Snapshot

Founded in January 2013, Aramon Neuro-Medical operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a new drug formulation for Parkinson's patients.

Business overview

Aramon Neuro-Medical is a pharmaceutical company developing a novel drug formulation, administered with a medical device, targeting Parkinson's patients resistant to oral dopamine treatment. The company's core technology involves a short-acting dopamine compound designed for continuous subcutaneous infusion, aiming to provide individualized treatment and avoid risks associated with existing therapies like percutaneous enterogastrostomy or deep brain stimulation. Aramon Neuro-Medical operates within the biotechnology and drug delivery sectors, focusing on treatments for Parkinson's disease.

Company Intelligence Q&A

What is Aramon Neuro-Medical's primary focus?

Aramon Neuro-Medical focuses on developing a new drug formulation for severely ill Parkinson's patients who are resistant to oral dopamine treatment.

What is the key innovation in Aramon Neuro-Medical's drug compound?

The company's compound is a short-acting dopamine designed for continuous subcutaneous infusion at low doses, allowing for personalized treatment and avoiding invasive procedures.

What problem does Aramon Neuro-Medical aim to solve?

Aramon Neuro-Medical addresses the unmet medical need for approximately 10% of Parkinson's patients who do not respond to standard oral dopamine therapies.

What is the current product stage of Aramon Neuro-Medical's development?

Aramon Neuro-Medical's product is currently in the R&D stage, focusing on developing a novel drug formulation for Parkinson's patients.

What are the potential benefits of Aramon Neuro-Medical's treatment approach?

The subcutaneous infusion method aims to significantly improve 'OFF' time and dyskinesias, while avoiding the risks associated with percutaneous enterogastrostomy (PEG) or deep brain stimulation (DBS).